Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;78(8):1321-1330.
doi: 10.1007/s00228-022-03345-8. Epub 2022 Jun 2.

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia

Bharati Shriyan #  1 , Parsshava Mehta #  1 , Anand Patil  1 , Shraddha Jadhav  1 , Sharath Kumar  1 , Apeksha S Puri  1 , Ravina Govalkar  1   2 , Manjunath Nookala Krishnamurthy  1   3 , Sachin Punatar  4   3 , Anant Gokarn  4   3 , Navin Khattry  4   3 , Vikram Gota  5   6
Affiliations

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia

Bharati Shriyan et al. Eur J Clin Pharmacol. 2022 Aug.

Abstract

Purpose: Imatinib is a substrate of CYP3A4, ABCB1 and ABCG2, and is known to have wide variability in pharmacokinetics (PK). At the same time, a clear relationship between drug levels and response also exists for imatinib in chronic myeloid leukaemia (CML). Therefore, pharmacogenetic-based dosing of imatinib is an attractive proposition. This study aims to characterize the population pharmacokinetics of imatinib in order to identify significant covariates including pharmacogenetic variants.

Methods: Forty-nine patients with CML were enrolled in the study after being on imatinib for at least 4 consecutive weeks. Steady-state pharmacokinetic sampling was performed either in a sparse (4 samples each, n = 44) or intensive manner (9 samples each, n = 5). An additional pharmacogenetic sample was also collected from all patients. Plasma imatinib levels were estimated using a validated HPLC method. Pharmacogenetic variants were identified using the PharmacoScan array platform. Population pharmacokinetic analysis was carried out using NONMEM v7.2. Seven SNPs within CYP3A4, ABCB1 and ABCG2 genes were evaluated for covariate effect on the clearance of imatinib.

Results: Imatinib PK was well characterized using a one-compartment model with zero-order absorption. The clearance and volume of distribution were found to be 10.2 L/h and 389 L respectively. Only SNP rs1128503 of the ABCB1 gene had a small but insignificant effect on imatinib clearance, with a 25% reduction in clearance observed in patients carrying the polymorphism. Twenty-three out of forty-nine patients (47%) carried the polymorphic allele, of whom 17 were heterozygous and six were homozygous.

Conclusion: Our study conclusively proves that genetic polymorphisms in the CYP3A4 and ABC family of transporters do not have any role in the personalized dosing of imatinib in CML.

Keywords: ADME; Imatinib; Pharmacogenetics; Pharmacokinetics; Population pharmacokinetics.

PubMed Disclaimer

References

    1. Hu Y, Li Q, Hou M et al (2021) Magnitude and temporal trend of the chronic myeloid leukemia: on the basis of the Global Burden of Disease Study 2019. JCO Glob Oncol 1429–1441. https://doi.org/10.1200/GO.21.00194
    1. Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. JCO 22:935–942. https://doi.org/10.1200/JCO.2004.03.050 - DOI
    1. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037. https://doi.org/10.1056/NEJM200104053441401 - DOI - PubMed
    1. Bhutani N (2020) Chronic myeloid leukemia in India: a review. https://doi.org/10.5281/ZENODO.3926873
    1. Adeagbo BA, Olugbade TA, Durosinmi MA et al (2017) Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: clinical implications for dosing and resistance. J Clin Pharmacol 57:1554–1563. https://doi.org/10.1002/jcph.953 - DOI - PubMed

MeSH terms

LinkOut - more resources